<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seminal abnormalities are commonly found during sulphasalazine treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Although these changes appear reversible after <z:e sem="disease" ids="C0152128" disease_type="Disease or Syndrome" abbrv="">drug withdrawal</z:e> this may result in <z:hpo ids='HP_0002583'>colitis</z:hpo> relapse </plain></SENT>
<SENT sid="2" pm="."><plain>Animal studies suggest that <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi>, the active component of sulphasalazine, does not impair fertility </plain></SENT>
<SENT sid="3" pm="."><plain>Sixteen patients with quiescent <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> were studied </plain></SENT>
<SENT sid="4" pm="."><plain>Each patient produced three samples of semen at weekly intervals </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 48 samples analysed 39.6% showed <z:hpo ids='HP_0000798'>oligospermia</z:hpo>, 41.7% showed an increased number of abnormal forms and 91.7% showed impaired motility </plain></SENT>
<SENT sid="6" pm="."><plain>Nine patients substituted enteric coated <z:chebi fb="0" ids="6775">mesalazine</z:chebi> (<z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi>) for sulphasalazine for a minimum period of three months </plain></SENT>
<SENT sid="7" pm="."><plain>During this time one patient developed a salmonella associated <z:hpo ids='HP_0002583'>colitis</z:hpo> relapse; the others remained well </plain></SENT>
<SENT sid="8" pm="."><plain>Improvement in sperm count (p less than 0.02), motility (p less than 0.001) and <z:mp ids='MP_0000002'>morphology</z:mp> (p less than 0.02) occurred in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="9" pm="."><plain>To date, four successful pregnancies have resulted, three in couples complaining of long term <z:hpo ids='HP_0000789'>infertility</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Treatment with enteric-coated <z:chebi fb="0" ids="6775">mesalazine</z:chebi> allows the recovery of seminal abnormalities induced by sulphasalazine in patients with <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
</text></document>